摘要
目的：分析探讨生物梅里埃产葡萄球菌药敏试剂盒 ATB STAPH 5在临床运用中存在的缺陷，并提出补救／解决方案。方法以 CLSI M100-S23提供的葡萄球菌对应抗生素拐点作为标准，对梅里埃药敏试剂盒 ATB STAPH 5抗生素覆盖情况与各抗生素拐点浓度进行对比分析。结果ATB STAPH5试剂盒不包括 CLSI 推荐的氯霉素类和恶唑烷酮类、脂肽类三类抗生素；ATB STAPH 5试剂盒提供的16种抗生素拐点均与 CLSI M100-S23推荐抗生素拐点不一致，从而可能导致临床药敏报告出现假敏感或假耐药的情况。结论在现行 CLSI 参考标准下，单独使用 ATB STAPH 5试剂盒进行葡萄球菌药敏试验将产生较大误差甚至错误，必须要其他药敏试验方法进行修正方可发出报告。
Objective To study the limitation analysis of Staphylococcus spp Susceptibility Test Kit ATB STAPH 5 from Bi-oMerieux in clinical application and to propose remedy.Methods The coverage area and break point of antibiotics ATB STAPH 5 from BioMerieux were analysed by using CLSI M100-S23 as standard.Results The kit ATB STAPH 5 did not include chloromycetin,oxazolidinones and lipopeptide three antibiotics that were recommend by CLSI.The 16 kinds of antibi-otics break point in the kit ATB STAPH 5 were all not inconsistent or did not contain with the standard of CLSI M100-S23. It may lead to error drug sensitivity tests,false sensitive or false drug resistance.Conclusion Only using this kit ATB STAPH 5 for Staphylococcus spp ,it may occurre errors or mistakes.Other experiments must be corrected before the re-port.
出处
《现代检验医学杂志》
CAS
2015年第3期122-125,共4页
Journal of Modern Laboratory Medicine
关键词
生物梅里埃
药敏
葡萄球菌
局限性
biomerieux
susceptibility
staphylococcus spp
limitation
